Global Small Cell Lung Cancer (SCLC) Therapeutics Market Outline, Scope & Future Growth Forecast The market research report provides detailed analysis of market drivers, challenges, opportunity analysis, and trends, along with various key insights into the global bcg vaccines sales market research report.
BriefingWire.com, 3/12/2021 - The Global Small Cell Lung Cancer (SCLC) Therapeutics Market 2020-2030 Report provides an in-depth analysis on the studied market that helps to seem at the longer term requirement also as prediction. The global small cell lung cancer (sclc) therapeutics market Report evaluates the market by key market players, opportunities, value, trends, growth, market share, market competition landscape, recent developments and sales volume analysis. Additionally, it magnifies the chance for decision-making and helps create an efficient counter-strategy to realize a competitive advantage. The report provides up-to-
Sunshine Biopharma Receives Notice of Allowance for a New Patent Application Extending Protection of Adva-27a in Europe Until 2033
March 11, 2021 09:00 ET | Source: Sunshine Biopharma Inc. Sunshine Biopharma Inc. Montreal, Quebec, CANADA
MONTREAL, March 11, 2021 (GLOBE NEWSWIRE) Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has received a “Notice of Allowance” from the European Patent Office for a new patent application covering Adva-27a, the Company’s flagship anticancer compound. This newly issued patent contains new subject matter and extends the proprietary protection of Adva-27a in Europe until 2033. The equivalent patent in the United States was issued in 2019 (US Patent Number 10,272,065) and similarly covers Adva-27a until 2033. The Canadian Intellectual Property recently i
Novel method can improve the detection of circulating tumor cells
Non-Small Cell Lung Cancer (NSCLC) is the most prevalent form of lung cancer, accounting for more than 80 percent of all lung cancer cases. Despite the aggressive nature of NSCLC, circulating tumor cells that lead to metastases often go undetected in the blood compared to breast, prostate, colorectal, and other cancers.
Now, scientists have developed a novel method to better detect the circulating tumor cells (CTCs) that are a telltale sign of metastases. The research was published in the journal
Proceedings of the National Academy of Sciences (
PNAS).
ISB and a collaborative team of researchers looked at hexokinase-2, or HK2, a key enzyme in glucose metabolism. A set of previous reports from our collaborator Dr. Herschman (co-author of the paper) and others revealed that cancer cells often rely on HK2 to elevate glucose metabolism to fuel their uncontrolled growth, making this enzyme a desirable target for test
A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients
Share Article
Institute for Systems Biology researchers and their collaborators have developed a novel method to better detect the circulating tumor cells in Non-Small Cell Lung Cancer patients. The cells circulate in the bloodstream and are a telltale sign of metastases.
Assistant Professor Dr. Wei Wei, left, and Bioinformatics Scientists Dr. Xiaowei Yan are pictured at Institute for Systems Biology in 2019. (Scott Eklund / Red Box Pictures) This approach will be useful in identifying circulating tumor cells from patients with a wide variety of cancers, independent of epithelial traits.” – Wei Wei, PhD, ISB Assistant Professor
A team of Roswell Park Comprehensive Cancer Center researchers has identified a new biomarker that could predict response to immune checkpoint inhibitors (ICI) shortly after patients with non-small cell lung cancer (NSCLC) initiate therapy.